Avage
- Generic Name: tazarotene
- Brand Name: Avage
Avage (Tazarotene) side effects drug center
- Related Drugs
- Health Resources
- Related Supplements
- Drug Comparison
- skin burning
- warmth
- stinging
- tingling
- itching
- redness
- swelling
- dryness
- peeling
- pain
- irritation
- rash, or
- acne
- severe skin irritation (pain, dryness, flaking, peeling, burning, stinging, itching) after applying the medicine;
- blistering or peeling skin;
- severe redness or discomfort; or
- swelling, warmth, oozing, or other signs of skin infection.
- dry, scaly, or peeling skin;
- skin pain, redness or burning; or
- itching or other irritation of treated skin.
What Is Avage?
Avage (tazarotene) Cream, 0.1% is a compound similar to vitamin A used to treat plaque psoriasis (psoriasis with scaly patches) and to treat facial acne. The Avage brand of tazarotene cream is used to reduce the appearance of fine wrinkles on the face, mottled light and dark skin patches on the face, and benign facial lentigines (noncancerous freckles).
What Are Side Effects of Avage?
Common side effects of Avage Cream include:
Dosage for Avage
Apply a pea-sized dose of Avage Cream once a day at bedtime to lightly cover the entire face including the eyelids if desired. Remove makeup before applying Avage. Facial moisturizers may be used as desired.
What Drugs, Substances, or Supplements Interact with Avage?
Avage Cream may interact with hiazide diuretics, antibiotics, phenothiazines, other topical products with a strong drying effect, products with high concentrations of alcohol, astringents, spices, peel of lime, medicated soaps or shampoos, permanent wave solutions, electrolysis, chemical hair removers or waxes, or other products that might dry or irritate the skin. Tell your doctor all medications and supplements you use.
Avage During Pregnancy or Breastfeeding
Avage Cream should not be used during pregnancy. It may harm a fetus. Women should have a negative pregnancy test within 2 weeks prior to starting this drug. Consult your doctor about using birth control. It is unknown if this drug passes into breast milk. Consult your doctor before breastfeeding.
Additional Information
Our Avage (tazarotene) Side Effects Drug Center provides a comprehensive view of available drug information on the potential side effects when taking this medication.
Get emergency medical help if you have signs of an allergic reaction: hives; difficult breathing; swelling of your face, lips, tongue, or throat.
Stop using tazarotene topical and call your doctor at once if you have:
Common side effects may include:
This is not a complete list of side effects and others may occur. Call your doctor for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088.
Read the entire detailed patient monograph for Avage (Tazarotene)
SIDE EFFECTS
In human dermal safety studies, tazarotene 0.05% and 0.1% creams did not induce allergic contact sensitization, phototoxicity or photoallergy.
The most frequent treatment-related adverse reactions ( ≥ 5%) reported during the clinical trials with AVAGE® (TAZAROTENE) Cream 0.1% in the treatment of facial fine wrinkling, mottled hypo- and hyperpigmentation, and benign facial lentigines were limited to the skin. Those occurring in >10%, in descending order, included: desquamation, erythema, burning sensation, and dry skin. Events occurring in ≥ 1% to ≤ 10% of patients, in descending order included: skin irritation, pruritus, irritant contact dermatitis, stinging, acne, rash or cheilitis. Common adverse events observed in the clinical trials are presented in the following table:
TABLE OF ADVERSE EVENTS SEEN IN CLINICAL TRIALS WITH AVAGE®
(TAZAROTENE) Cream 0.1%
| Adverse Event | AVAGE ® N=567 |
Vehicle N=564 |
| Desquamation | 40% | 3% |
| Erythema | 34% | 3% |
| BurningSensation | 26% | <1% |
| DrySkin | 16% | 3% |
| Irritation Skin | 10% | 1% |
| Pruritus | 10% | 1% |
| Irritant Contact Dermatitis | 8% | 1% |
| Stinging | 3% | <1% |
| Acne | 3% | 3% |
| Rash | 3% | 1% |
| Cheilitis | 1% | 0% |
A few patients reported adverse events at Week 0; however, for patients who were treated with AVAGE® (tazarotene) the highest number of new reports for each adverse event was at Week 2.
When combining data from the two pivotal studies, 5.3% of patients in the tazarotene cream group and 0.9% of patients in the vehicle group discontinued due to adverse events.
Overall, 20/567 (3.5%) patients in the AVAGE® (TAZAROTENE) Cream 0.1% group and 16/564 (2.8%) patients in the vehicle group reported adverse events (including edema, irritation, and inflammation) directly related to the eye or eyelid. The majority of these conditions were mild.
Read the entire FDA prescribing information for Avage (Tazarotene)
© Avage Patient Information is supplied by Cerner Multum, Inc. and Avage Consumer information is supplied by First Databank, Inc., used under license and subject to their respective copyrights.